Semaglutide linked to first reported case of gastric pneumatosis—air in the stomach wall
First case report of gastric pneumatosis (air in the stomach wall) associated with semaglutide use, adding a rare but potentially serious GI complication to the expanding GLP-1 drug safety profile.
Quick Facts
What This Study Found
First case: gastric pneumatosis on semaglutide. Novel GI complication not previously described. GLP-1 drugs cause delayed gastric emptying (possible mechanism). Can be benign or indicate serious pathology.
Key Numbers
How They Did This
Single case report.
Why This Research Matters
With millions on semaglutide, even rare GI complications must be documented. Gastric pneumatosis can sometimes indicate life-threatening conditions, making recognition important.
The Bigger Picture
The GLP-1 drug GI side effect spectrum continues to expand: from nausea to gastroparesis to intussusception to now gastric pneumatosis. Each new report refines the safety picture for clinicians.
What This Study Doesn't Tell Us
Single case. Cannot prove causation. Very rare. Gastric pneumatosis has multiple causes.
Questions This Raises
- ?Is the pneumatosis from delayed gastric emptying or another mechanism?
- ?How should gastric pneumatosis on GLP-1 drugs be managed?
- ?Should imaging findings be interpreted differently in GLP-1 drug users?
Trust & Context
- Key Stat:
- First gastric pneumatosis case Semaglutide is associated with the first reported case of air in the stomach wall—a novel GI complication expanding the growing safety profile of GLP-1 drugs
- Evidence Grade:
- Single case report—first description.
- Study Age:
- Published in 2025.
- Original Title:
- Semaglutide-Associated Gastric Pneumatosis.
- Published In:
- ACG case reports journal, 12(1), e01579 (2025)
- Authors:
- Turunen, Andrew M, Coombs, Reilly A, Garg, Sushil Kumar
- Database ID:
- RPEP-13844
Evidence Hierarchy
Frequently Asked Questions
What is gastric pneumatosis?
It is air trapped within the wall of the stomach, visible on imaging. It can be a harmless finding or indicate serious problems like reduced blood flow or infection. This is the first case reported in a semaglutide user, possibly related to the drug's effects on stomach motility.
Should I be worried about this on semaglutide?
This is extremely rare—a single case in millions of users. However, if you have unusual abdominal symptoms on semaglutide beyond typical nausea (severe pain, distension), seek medical attention. Most GI side effects of GLP-1 drugs are mild and manageable.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13844APA
Turunen, Andrew M; Coombs, Reilly A; Garg, Sushil Kumar. (2025). Semaglutide-Associated Gastric Pneumatosis.. ACG case reports journal, 12(1), e01579. https://doi.org/10.14309/crj.0000000000001579
MLA
Turunen, Andrew M, et al. "Semaglutide-Associated Gastric Pneumatosis.." ACG case reports journal, 2025. https://doi.org/10.14309/crj.0000000000001579
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide-Associated Gastric Pneumatosis." RPEP-13844. Retrieved from https://rethinkpeptides.com/research/turunen-2025-semaglutideassociated-gastric-pneumatosis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.